DnD 2024 backgrounds grant characters stat increases, a starting feat, a range of proficiencies, and a clear backstory. This is a major shake-up to the original Dungeons and Dragons 5e rules, and it ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...

In a 2023 Healthline survey, 79% of those who reported being interested in trying CBD said they were specifically interested in CBD gummies. And while older adults are interested in CBD as a pain ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...

In 2019, Stan­ford Uni­ver­si­ty pro­fes­sor Irv Weiss­man and a col­league pub­lished a pa­per that rep­re­sent­ed a new way to tar­get some ag­gres­sive can­cers.

Prolium was set up by RTW in 2024. Last year also saw the New York-based investment fund involved in the launch of obesity biotech Kailera Therapeutics, which RTW said at the time was the fourth ...

But local biotech leaders see signs of change in 2025. Amid tough biotech industry market conditions last year, investors and Big Pharma companies were more likely to make deals with later-stage ...

The Chi­na-to-US ex­per­i­men­tal med­i­cine pipeline is bal­loon­ing: yet an­oth­er US-based biotech formed around a can­di­date from Chi­na’s Keymed Bio­sciences on Mon­day.

Credit: uniquepixel via Getty Images. Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific ...